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ABSTRACT
Protective antigen (PA) produced by Bacillus anthracis is a highly immunogenic protein. Therefore, it has 
significant importance in serodiagnosis as well as a vaccine candidate for anthrax. In the present study, codons for 
PA gene were optimised and synthesised for its expression in Escherichia coli. Various expression conditions were 
optimised for scaled up production of rPA. The final yield of affinity chromatography purified protein was 40.8 
mg/l during batch fermentation. For further purification, affinity purified protein was diafiltered and subjected to 
anion exchange chromatography. SDS-PAGE and Western blot was used to characterise the purified rPA protein. 
The diagnostic potential of purified rPA was evaluated in Western blot using standards reference serum AVR 801 
and cutaneous anthrax clinical sera. The results of the present study established the optimum production of rPA in 
E. coli after codon optimisation for its subsequent use in diagnosis of anthrax infection.
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1. INTRODUCTION
Bacillus anthracis, the etiological agent of anthrax is a 
Gram positive, rod shaped and endospore forming bacteria1. 
Primarily, anthrax is a zoonotic and fatal disease which can 
spread from infected animals to other animals as well as human 
being2. However, chances of its spread from human to human 
are very scanty. Generally, human gets infected incidentally by 
contact with either diseased animals or their products like skin, 
meat or hides. In human, mainly there are three routes anthrax 
infection; through skin (cutaneous), by inhalation (pulmonary), 
and by eating (gastrointestinal)3. However, recently a new mode 
of infection known as injectional anthrax has also been known 
which spreads through the infected needles in drug users4,5. 
The pulmonary and gastrointestinal anthrax are considered as 
the most fatal, whereas cutaneous anthrax is most common. 
The toxicity and pathogenicity of B. anthracis is due to its 
tripartite toxins encoded by the genes present on pXO1 plasmid 
and capsule encoded by the genes present on pXO2 plasmid, 
respectively. The tripartite toxin consists of protective antigen 
(PA), lethal factor (LF), and edema factor (EF), which are of 83 
kDa, 90 kDa and 89 kDa, respectively6. PA itself is non-toxic, 
however on combination with LF and EF, it makes the lethal 
toxin and edema toxin, respectively. Hence, being the central 
component of both the toxins, it is one of the best choice for 
diagnostic markers7-11. Besides, PA is highly immunogenic, and 
therefore has been the best choice for development of vaccine 
candidates for anthrax12,13. 
Hence, PA is required for development of diagnostic as 
well as prophylactic systems for anthrax. For development of 
any detection/diagnostic assay or for vaccine purpose, high 
yield production of recombinant protein is required. Owing to 
risk involved in handling the B. anthracis culture for production 
and purification of native PA, it is always desirable to produce 
recombinant PA (rPA) in heterologous host. However, due to 
differences in codon preferences between B. anthracis and E. 
coli, problems arises in expression of B. anthracis genes cloned 
in E. coli. Hence, in this study, we optimised the codons of B. 
anthracis PA gene for its expression in E. coli to construct a 
synthetic gene. Further scale up and purification were done for 
rPA protein. The purified protein was used for the serodiagnosis 
of anthrax infection. 
2. MATERIALS AND METHODS
2.1 Codon Optimisation and Cloning of pag Gene
The sequence of B. anthracis pag gene was extracted 
from GenBank Accession No. AF306782.1 and the most 
favored codons of E. coli were selected according to the codon 
usage Database and graphical codon usage analyzer. The 
study was approved by Institutional Biosafety Committee of 
Defence Research and Development Establishment, DRDO, 
Ministry of Defence, Government of India vide protocol no. 
IBSC/19/BPD/AKG/3. The optimised gene with the restriction 
sites (NdeI & XhoI) was custom synthesised by Bio Basic Inc, 
Canada. The custom synthesised pag gene was sub-cloned into 
the pET30a+ vector and transformed into E. coli BL21 (DE3) 
for the expression of protein. Received : 12 August 2019, Revised : 17 September 2019 
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2.2 Inducible Expression of Codon Optimised PA 
in Shake Flask Cultures
The transformed E. coli was grown at 37 °C in LB broth 
(10 ml test tube) with kanamycine (30 μg/ ml) and after getting 
the optical density (OD) of 0.5-0.6 at 600 nm, 1.0 mM IPTG 
was added to induce the expression. After 4 h of induction, 
the cultures were centrifuged at 8000 rpm for 10 min at 4 °C 
and washed twice with triple distilled water. For expression 
screening, washed pellet (from 1 ml of 4 h induced culture) 
was resuspended in 100 µl cell lysis buffer by vortexing. After 
centrifugation, the supernatant was carefully removed and 
characterised on SDS-PAGE. Histidine tag at C-terminal in the 
recombinant protein was confirmed with anti-His antibody by 
Western blot.
Effect of inducer concentration, induction time and 
induction temperature was studied for enhanced expression 
of PA. For inducer concentration trials, different IPTG 
concentrations 0.5 mM, 0.75 mM, 1.0 mM, and 1.5 mM for 
fixed time (4 h) at 37 °C was checked in LB media. To optimise 
induction duration, the cultures were induced with 1 mM 
IPTG for 4 h and 16 h and for optimisation of post induction 
temperature, the cultures were grown as above and subjected 
to temperature of 25 °C and 37 °C. Cells were harvested by 
centrifugation and after lysis, supernatant of all the samples 
were analysed by SDS-PAGE for protein expression. 
To further increase the rPA expression level, cultivation media 
were also optimised. To 10 ml each of the five different media 
Luria martini broth (LB), super broth (SB), super optimal 
broth (SOB), super optimal broth with catabolite repression 
(SOC) and terrific broth (TB) with antibiotics in duplicate 
were inoculated with 1 ml of overnight grown culture. After 
attaining OD 600 nm of about 0.5-0.9, the culture was induced 
with IPTG (1.0 mM). After 4 h post induction, cultures were 
harvested using centrifugation.
2.3 Batch Fermentation Studies
Further, rPA was bulk produced in a 5 litre working 
volume bioreactor (Bioflo 3000: New Brunswick, uSA). For 
each fermentation run, a 50 ml LB broth with antibiotics was 
inoculated with 1 ml of stock culture and incubated at 180 
rpm for 8 h at 37 °C. Further, 400 ml sterile TB medium with 
antibiotic was inoculated with above grown culture (1% v/v) 
and incubated at 180 rpm for 14 h at 37 °C. This inoculum was 
used as seed (5% v/v) for 4.5 l of TB medium with antibiotic 
in Bioreactor vessel. Initially, the temperature, pH, agitation 
rate and air flow rate of bioreactor were kept as 37 °C, 
7.0, 100 rpm and 2.5 LPM, respectively . After induction, 
the cultivation temperature was maintained at 37 °C, whereas 
the rate of aeration varied between 0.5 VVM to 2.0 VVM. 
The dissolved oxygen (DO) was kept at 20 per cent - 30 per 
cent of air saturation by varying agitation rate between 100 
rpm and 400 rpm as well as using pure oxygen with air, if 
necessary. The cultivation pH was controlled between pH 6.8 





whenever required. Antifoam was added to prevent foaming 
during cultivation. After 4 h of inoculation when the culture 
reached to mid log phase, 1 mM IPTG was added to induce the 
protein expression. After 4 h of induction, the cell pellet was 
recovered by centrifugation of culture at 8000 rpm for 30 min 
at 4 °C. The growth of culture in bioreactor was monitored at 
regular intervals by measuring OD at 600 nm.
2.4 Purification of rPA using Affinity and Ion 
Exchange Chromatography
For purification of rPA, cell pellet was washed twice with 
distilled water followed by washing with cell wash buffer14. 
The cells were further dissolved in cell lysis buffer as explained 
previously14 and sonicated for 10 min with 9 s on and off using 
sonicator (Biologics, uSA). The homogenate was clarified by 
centrifugation at 8,000 rpm for 45 min and the collected pellet 
washed with IB wash buffer-1 followed by IB wash buffer-214. 
The solubilisation buffer (100 mM NaH2PO4, 10 mM Tris-Cl, 
300 mM NaCl, 8 M urea, pH 8.0) was added to the washed 
pellet and incubated overnight at 4 °C on magnetic stirrer 
for purification. After filtering the supernatant through 0.45 
µm membrane, immobilised metal affinity chromatography 
was used for purification of PA. A 5 ml pre-packed Ni-NTA 
affinity chromatography column was pre equilibrated using 
equilibration buffer (100 mM NaH2PO4, 10 mM Tris-Cl, 300 
mM Nacl, 8 M urea, pH 8.0). The pre-packed column was 
obtained from Qiagen, Germany and used in AKTA explorer 
system (GE Healthcare Life Sciences, uSA). After loading 
the sample, column was washed using wash buffer (100 mM 
NaH2PO4, 10 mM Tris-Cl, 300 mM Nacl, 8 M urea, pH 6.3) 
with 10 column volume. The protein was eluted in elution buffer 
(100 mM NaH2PO4, 10 mM Tris-Cl, 300 mM Nacl, 8 M urea, 
pH 4.5) and analysed by SDS-PAGE. The eluted fractions were 
pooled and diafiltered using decreasing concentration of urea 
from 6 M to 0 M.
Ion exchange chromatography (IEX) was used after 
diafiltration of IMAC purified rPA for its further purification. 
For IEX, diafiltered sample was loaded onto the column 
containing pre-equilibrated Q-Sepharose anion exchange 
resin. Column was washed with 10 CV of wash buffer (10 
mM Tris-Cl, 100 mM NaCl, pH 6.0) and bound proteins were 
eluted with ion exchange elution buffer (10 mM Tris-Cl, 300 
mM NaCl, pH 6.0). Elutes were analysed by SDS-PAGE and 
quantified by BCA assay. The purified rPA was stored at – 80 
°C for further use.
2.5 Evaluation for Diagnostic Potential by Western 
Blot Analysis
The purified rPA was evaluated for its diagnostic potential 
by Western blot analysis with clinical sera sample10. After 
separation of rPA on 12 per cent SDS-PAGE, it was transferred 
to PVDF membrane and blocked with 5 per cent skimmed milk 
powder (SMP) in phosphate-buffered saline (PBS) at 4 °C for 
16 h. Blocked membranes were washed thrice for 5 min with 
PBS containing 0.1 per cent Tween-20 (v/v) and incubated at 
37 °C for 1 h with anthrax infected patient sera (1:100 dilution 
in PBS containing1 per cent SMP). Standard reference serum 
AVR 801 (gifted by Dr Conrad P. Quinn, CDC, Atlanata) was 
also used in the study. After washing, the membranes were 
incubated with (Fc specific) HRP conjugated goat anti-human 
IgG (Sigma, uSA) for 1 h at 37 °C in 1: 500 dilutions in PBS 
containing 1 per cent SMP. After washing, the membranes were 
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developed in diaminobenzidine (DAB)/H2O2 substrate solution 
for 15 min at 37 °C. 
3. RESULTS AND DISCUSSIONS
3.1 Codon Optimisation of PA Gene
The transformed E. coli yields the best expression of 
genes with preferential codons that are recognised by abundant 
tRNA species15. Hence, to improve the expression of PA of 
B. anthracis, the codons of its pag gene were altered within 
the gene sequence and a synthetic gene was designed and 
constructed as shown in Fig. 1. The synthetic gene comprised 
of the optimally expressed codons of E. coli, without altering 
the amino acid sequence. Thus, codon optimised sequence was 
used to increase protein expression. 
3.2 Expression of Codon Optimised rPA
The synthetic PA gene was cloned in vector pET30a+ 
vector and transformed in E. coli BL21 (DE3). A protein of 83 
kDa was evident in induced culture, whereas no protein was 
observed in un-induced culture, confirming the expression of 
PA in induced culture as shown in Fig. 2(a). Further, the rPA 
was confirmed by Western blotting with anti-His antibody as 
shown in Fig. 2(b). 
3.3 Optimisation of Culture Conditions for High 
Production
Various parameters including concentration of IPTG, 
induction time and temperature were optimised for optimum 
production of rPA. The SDS PAGE profile depicting the 
effect of inducer concentration, and induction temperature 
and time has been shown in Figs. 3(a) and 3(b), respectively. 
Varying IPTG concentrations starting from 0.5 mM to 1.5 mM 
didn’t affect protein expression at significant level as shown 
in Fig. 3(a). Therefore, IPTG concentration of 1 mM was 
selected for further studies. Maximum protein expression was 
found at 4 h of induction as compared to 16 h as shown in Fig. 
3(b). Further, it was concluded that expression of protein at 37 °C 
was higher than at 25 °C as shown in Fig. 3(b). 
Figure 1. Sequence of the original (Org) and the optimised (Opt) PA gene. Black dots represent the identical residues.
Figure 2. Expression profile of rPA. (a) SDS-PAGE profile of 
expressed protein. Lane 1, MW marker; lane 2 Un-
induced culture; lane 3, Induced culture containing 
rPA. (b) Western blot analysis to confirm expression 
of rPA. Lane 1, MW marker; lane 2, Induced culture; 
lane 3, Un-induced culture.
(a) (b)
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To improve the expression of rPA, five different media 
were tested at shake flask culture conditions. These media gave 
different growth and protein expression profile. However, the 
TB medium performed the best in the present study for enhanced 
expression of rPA in E. coli as shown in Fig. 4. The SDS-PAGE 
profile for localisation study of expressed rPA showed that 
majority of the expressed protein was in insoluble form. 
therapeutics potential16. using TB growth media, batch 
fermentation yielded about three times higher wet biomass 
in comparison to shake flasks in this study.
3.5 Purification and Characterisation of rPA
The rPA was purified from the biomass obtained from 
shake flask cultures as well as batch fermentation processes. 
The desired protein of 83 kDa aggregated in the inclusion 
bodies (IBs). From the lysed cell mass, IBs were harvested, 
solubilised in 8 M urea buffer and purified by IMAC. The 
rPA was eluted with elution buffer, pH 4.5 as shown in 
Fig. 5 followed by diafiltration. The diafiltered protein was 
further purified by ion exchange chromatography.
In TB medium, the rPA yield was 40.8 mg/l and 
19.0 mg/l in batch process and shake flask culture, 
respectively after IMAC as shown in Table 1. A final 
yield of more than 2-times rPA was obtained in batch 
process than shake flask culture as shown in Table 1. The 
SDS–PAGE analyses corroborated that highly pure rPA 
could be recovered using chromatographic purification 
Figure 4. SDS-PAGE analysis for effect of different media on 
expression of rPA. Lane 1, MW marker; lane 2, Un-
induced culture; lane 3, LB; lane 4, SOB; lane 5, SB; 
lane 6, SOC; lane 7, TB medium.
3.4 Scale up of rPA using Bioreactor
Batch fermentation was used for enhanced production of 
rPA. The parameters optimised at small scale were employed 
in 5 liter bioreactor. For scale-up, cultures were grown in TB 
medium followed by induction with 1 mM IPTG. Dissolved 
oxygen (DO) level was maintained above 20 per cent during 
bioreactor cultivations by agitation (100-400 rpm), aeration 
and/or using pure oxygen. Initially DO level was more than 
30 per cent, which gradually decreased with culture growth. 
Finally, a wet cell weight of 14. 5 g/l was achieved after batch 
cultivation.
Generally, the recombinant proteins are required in higher 
amounts for development of detection or protection systems. 
For bulk production of such protein, scale-up process needs 
to be optimised. Batch fermentation is the ideal tool for bulk 
production of proteins with diagnostics, prophylactics or 
Figure 5. Chromatogram of affinity purification of rPA.
Figure 6. Purification and characterisation of rPA. (a) SDS 
PAGE. Lane 1, MW marker; lane 2, purified protein. 
(b) Western blot.  Lane 1, MW marker; lane 2, Purified 
protein.
(a) (b)
Figure 3. SDS-PAGE analysis for effect of inducr concentration and 
post induction time and temperature on expression of rPA. 
(a): Effect of inducer concentration. Lane 1, MW marker; 
lane 2, Un-induced culture; lane 3, 0.25 mM; lane 4, 0.75 
mM; lane 5, 1.0 mM; lane 6, 1.5 mM. (b): Effect of time 
and temperature. Lane 1, MW marker; lane 2, Un-induced 
culture; lane 3, 25 oC/ 4 h; lane 4, 37 oC/ 4 h; lane 5, 25 oC/ 
16 h; lane 6, 37 oC/ 16 h.
(a) (b)
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 as shown in Fig. 6(a). The purified rPA was then subjected 
to western blot assay using anti-his antibody as shown in 
Fig. 6(b).
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LB Shake flask 2.1 7.2
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